Sequencing several metastases from the same man showed they are genetically much more alike than metastases from different men, so one good biopsy usually represents the rest.
Multiple tumours from men with disseminated prostate cancer were analysed by whole-exome sequencing, array comparative genomic hybridisation and RNA transcript profiling, and genomic diversity within and between individuals was compared. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual: the number of somatic mutations, the burden of copy-number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor activity and cell-cycle activity. Androgen receptor activity was inversely associated with cell proliferation, while expression of Fanconi anaemia complex genes correlated with elevated cell-cycle progression, E2F1 expression and RB1 loss. Men with somatic aberrations in Fanconi anaemia complex genes or in ATM had significantly longer responses to carboplatin than men without DNA repair gene defects.
It is the reason a single metastatic biopsy is defensible in this disease, where in lung and bowel cancer heterogeneity makes one sample a gamble. The caveat is that it applies to driver alterations and not to the polyclonal resistance events that appear under treatment.
Shares Biopsy, ATM, RB1, Androgen receptor signalling.
Shares RB1, Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired).
Shares ATM, Androgen receptor signalling, Double-strand break repair: HR versus end joining, Castration-resistant prostate cancer (CRPC).
Shares RB1, Nature Medicine, Clonal evolution & minimal residual disease, Castration-resistant prostate cancer (CRPC).
Shares Androgen receptor signalling, Double-strand break repair: HR versus end joining, Castration-resistant prostate cancer (CRPC), Androgen receptor.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Androgen receptor.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Androgen receptor.
Shares Biopsy, RB1, Androgen receptor signalling, Clonal evolution & minimal residual disease.